Insulet Co. (NASDAQ:PODD) Director David A. Lemoine sold 641 shares of the business’s stock in a transaction on Tuesday, March 6th. The stock was sold at an average price of $76.81, for a total value of $49,235.21. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Shares of Insulet Co. (NASDAQ PODD) traded up $0.67 during mid-day trading on Friday, reaching $80.33. The company had a trading volume of 297,863 shares, compared to its average volume of 463,309. Insulet Co. has a 1 year low of $38.43 and a 1 year high of $83.56. The company has a current ratio of 6.24, a quick ratio of 5.85 and a debt-to-equity ratio of 3.57. The stock has a market cap of $4,690.55, a P/E ratio of -174.63 and a beta of 1.56.
Insulet (NASDAQ:PODD) last announced its earnings results on Wednesday, February 21st. The medical instruments supplier reported ($0.12) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.08) by ($0.04). Insulet had a negative return on equity of 29.73% and a negative net margin of 5.79%. The business had revenue of $130.50 million for the quarter, compared to analysts’ expectations of $125.16 million. During the same quarter last year, the firm earned ($0.16) earnings per share. The firm’s quarterly revenue was up 26.0% compared to the same quarter last year. sell-side analysts predict that Insulet Co. will post -0.3 EPS for the current year.
A number of hedge funds have recently made changes to their positions in the stock. Rehmann Capital Advisory Group purchased a new position in Insulet during the 4th quarter worth $375,000. Xact Kapitalforvaltning AB purchased a new position in Insulet during the 4th quarter worth $381,000. Segall Bryant & Hamill LLC grew its stake in Insulet by 10.5% during the 4th quarter. Segall Bryant & Hamill LLC now owns 200,707 shares of the medical instruments supplier’s stock worth $13,849,000 after buying an additional 19,105 shares during the last quarter. MetLife Investment Advisors LLC purchased a new position in Insulet during the 4th quarter worth $1,804,000. Finally, Castleark Management LLC purchased a new position in Insulet during the 4th quarter worth $16,289,000.
ILLEGAL ACTIVITY NOTICE: “Insider Selling: Insulet Co. (PODD) Director Sells 641 Shares of Stock” was posted by Markets Daily and is owned by of Markets Daily. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at https://www.themarketsdaily.com/2018/03/11/insider-selling-insulet-co-podd-director-sells-641-shares-of-stock.html.
Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.